News|Articles|October 11, 2023

Sapio Sciences Launches New Molecule Solution Platform

Sapio chemistry solution unifies small-molecule and large-molecule discovery workflows on a single platform.

Sapio Sciences announced the launch of its Sapio chemistry solution, which unifies small-molecule and large-molecule discovery workflows on a single platform. According to the company, the technology enables scientists to draw insights across all their organization’s discovery experiments.

“Many organizations are still running decades-old electronic laboratory notebooks (ELNs) and other software for capturing chemical synthesis experiments and registering small molecules,” said Kevin Cramer, president, CEO, Sapio Sciences. “Large-molecule and small-molecule discovery have traditionally been managed on disparate systems, creating artificial islands that impede scientific collaboration and decision-making. Sapio is excited to give biopharma organizations the opportunity to consolidate all their chemistry experiments on a modern, unified lab platform.”

Reference

Sapio Sciences Unifies Small- and Large-Molecule Discovery on a Single Platform. Business Wire. October 9, 2023. Accessed October 10, 2023. https://www.businesswire.com/news/home/20231009525095/en/Sapio-Sciences-Unifies-Small--and-Large-Molecule-Discovery-on-a-Single-Platform


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.